Clinical Trial Update: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating vobramitamab duocarmazine in metastatic castration-resistant prostate cancer and other solid tumors was terminated, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Castration-resistant Prostate Cancer
• Head and Neck Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Malignant Melanoma
• Non-small Cell Lung Cancer
• Oral Squamous Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Vobramitamab duocarmazine (vobramitamab duocarmazine)

Snippet

Sponsor: MacroGenics | Conditions: Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-02-09